POLB 001 LPS Challenge Trial Paper Published

Summary by AI BETAClose X

Poolbeg Pharma PLC has announced the publication of peer-reviewed data from its POLB 001 LPS challenge trial in Frontiers in Immunology, confirming that POLB 001 significantly reduced key inflammatory biomarkers and immune cell recruitment, including neutrophils by 72.4%-81.5% and TNF by 35.3%-65.1%, while being safe and well-tolerated across all dose levels. The study validates POLB 001's potent inhibition of p38 MAPK driven cytokine responses and supports its potential to prevent cancer immunotherapy-induced Cytokine Release Syndrome, with interim data from the TOPICAL trial anticipated this summer.

Disclaimer*

UK 100

Latest directors dealings